No 01 2010

Elicera Therapeutics has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to move its CARMA study of the CAR T-cell therapy ELC-301 in B-cell lymphoma into Phase IIa.

A new study co-authored by Jonathan Ilicki, Life Science Strategy Lead at the Swedish venture capital firm Industrifonden, finds that investment and business-development professionals often misjudge rare-disease assets, underestimating launch performance and misreading when the assets are most commonly acquired.

Throughout her career, customer centricity and a passion for solving unmet medical needs have driven Norwegian Lena Nymo Helli. This year, she joined the Danish company Coloplast as Country Manager for Norway.

US President Donald Trump said on Friday September 18, 2026, that his administration plans to recommend that vaccine makers split certain childhood vaccines into five smaller doses given six months apart, which he expects to sharply reduce autism. He did not name the vaccines or cite evidence.

Novo Nordisk has outlined its strategic ambitions for 2030 at a Capital Markets Day in London, targeting more than five multi-blockbuster launches by 2030 and more than DKK 150 billion in risk-adjusted pipeline sales in 2035. The company also aims to serve more than 60 million patients globally by 2030.

Bavarian Nordic has appointed Tarja Stenvall as President and Chief Executive Officer, effective 15 October. She succeeds Paul Chaplin, whose departure was announced earlier this year.

The Life Science Cluster turns ten. But instead of looking in the rearview mirror, let's look at why life science will matter more over the next decade.